Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 101–200 of 1,002
Exploring rhizo-microbiome transplants as a tool for protective plant-microbiome manipulation
Jiang, G., Zhang, Y., Gan, G., Li, W., Wan, W., Jiang, Y., Yang, T., Zhang, Y., Xu, Y., Wang, Y., et al. (2022) · ISME Communications · doi:10.1038/s43705-022-00094-8 · Cited by 167
Nutritional regulation of microbiota-derived metabolites: Implications for immunity and inflammation
Arifuzzaman, M., Collins, N., Guo, C., & Artis, D. (2024) · Immunity · doi:10.1016/j.immuni.2023.12.009 · Cited by 168
Metabolic programs tailor T cell immunity in viral infection, cancer, and aging
Møller, S. H., Hsueh, P., Yu, Y.-R., Zhang, L., & Ho, P. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.003 · Cited by 163
Zhu, G., Su, H., Johnson, C. H., Khan, S. A., Kluger, H., & Lu, L. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.053 · Cited by 148
Predictive biomarkers of colon cancer immunotherapy: Present and future
Hou, W., Cheng, Y., & Zhu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032314 · Cited by 159
The gut microbiome: what the oncologist ought to know
Lee, K. A., Luong, M. K., Shaw, H., Nathan, P., Bataille, V., & Spector, T. D. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01467-x · Cited by 143
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
Zhao, W., Lei, J., Ke, S., Chen, Y., Xiao, J., Wang, L., Wang, L., Ren, Y., Alnaggar, M., Qiu, H., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102315 · Cited by 163
Impact of risk factors on early cancer evolution
Weeden, C. E., Hill, W., Lim, E. L., Gronroos, E. C., & Swanton, C. (2023) · Cell · doi:10.1016/j.cell.2023.03.013 · Cited by 193
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
Self-citationAdvances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi, H., Hsu, J.-M., Sun, L., Wang, S., & Hung, M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101621 · Cited by 167
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy
Han, Z., Li, Y.-B., Yang, L., Cheng, H., Liu, X., & Chen, H. (2021) · Molecules · doi:10.3390/molecules27010137 · Cited by 151
Huang, C., Yi, P., Zhu, M., Zhou, W., Zhang, B., Yi, X., Long, H., Zhang, G., Wu, H., Tsokos, G. C., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102844 · Cited by 149
Liu, Y., Wong, C. C., Ding, Y., Gao, M., Wen, J., Lau, H. C.-H., Cheung, A. H. K., Huang, D., Huang, H., & Yu, J. Q. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01695-w · Cited by 151
Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration
Jensen, B. A. H., Heyndrickx, M., Jonkers, D. M. A. E., Mackie, A. R., Millet, S., Naghibi, M., Pærregaard, S. I., Pot, B., Saulnier, D. M. A., Sina, C., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101190 · Cited by 188
Intestinal bacteria and colorectal cancer: etiology and treatment
Dougherty, M. W., & Jobin, C. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185028 · Cited by 159
Choi, Y., Lichterman, J. N., Coughlin, L. A., Poulides, N., Li, W., Del Valle, P., Palmer, S. N., Gan, S., Kim, J., Zhan, X., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.abo2003 · Cited by 132
Arance, A. M., de la Cruz‐Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Márquez‐Rodas, I., Spreafico, A., Atkinson, V. G., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00221 · Cited by 144
Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer
Chambers, L., Rhoades, E. E., Bharti, R., Braley, C., Tewari, S., Trestan, L., Alali, Z., Bayık, D., Lathia, J. D., Sangwan, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0455 · Cited by 144
Nanochemistry advancing photon conversion in rare-earth nanostructures for theranostics
Lv, R., Raab, M. E., Wang, Y., Tian, J., Lin, J., & Prasad, P. N. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214486 · Cited by 128
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota
Ohtani, N., & Hara, E. (2021) · Cancer Science · doi:10.1111/cas.15142 · Cited by 137
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 142
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Recent developments in immunotherapy for gastrointestinal tract cancers
Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 146
Costa, D. A., Nobre, J. G., Batista, M. V., Ribeiro, C., Callé, C., Cortés, A., Marhold, M., Negreiros, I., Borralho, P., Brito, M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.584332 · Cited by 140
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Zhang, C., Zhang, C., & Wang, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216182 · Cited by 127
Microbiota and prostate cancer
Rizzo, A., Santoni, M., Mollica, V., Fiorentino, M., Brandi, G., & Massari, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.007 · Cited by 130
Quantifying bias introduced by sample collection in relative and absolute microbiome measurements
Maghini, D. G., Dvorak, M., Dahlen, A., Roos, M., Doyle, B., Kuersten, S., & Bhatt, A. S. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01754-3 · Cited by 116
The gut microbiota in cancer immunity and immunotherapy
Xie, M., Li, X., Lau, H. C.-H., & Yu, J. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01326-2 · Cited by 138
Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective
Valles-Colomer, M., Menni, C., Berry, S. E., Valdes, A. M., Spector, T. D., & Segata, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02260-4 · Cited by 114
Wang, Y., Zhang, S., Borody, T. J., & Zhang, F. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002339 · Cited by 120
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 136
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Podlesny, D., Durdevic, M., Paramsothy, S., Kaakoush, N. O., Högenauer, C., Gorkiewicz, G., Walter, J., & Fricke, W. F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100711 · Cited by 111
“In addition, two recent trials suggest a potential role for FMT in cancer therapy, demonstrating re-induction of a response to anti-PD-1 immunotherapy in 30% of immune checkpoint inhibitor (ICI)-refractory melanoma patients (n = 25) after FMT from patients who had previously responded to ICI.(7,8) FMT is currently bei…”
BackgroundInfluentialEuropean Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Lawler, M., Davies, L., Oberst, S., Oliver, K. R., Eggermont, A. M. M., Schmutz, A., Vecchia, C. L., Allemani, C., Lievens, Y. N., Naredi, P. L. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00540-x · Cited by 130
Sun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
Chen, W., Wen, L., Bao, Y., Tang, Z., Zhao, J., Zhang, X., Wei, T., Zhang, J., Ma, T., Zhang, Q., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203894119 · Cited by 116
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.036 · Cited by 101
Advances in the study of emodin: an update on pharmacological properties and mechanistic basis
Zheng, Q., Li, S., Li, X., & Liu, R. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00509-z · Cited by 117
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
“Strategies to influence gut dysbiosis, such as fecal microbiota transplant, may make tumors more susceptible to immunotherapy, but these approaches are still in their infancy (73, 74).”
BackgroundŠevčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
Aghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Xu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.949490 · Cited by 126
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
Pingili, A. K., Chaib, M., Sipe, L. M., Miller, E. J., Teng, B., Sharma, R., Yarbro, J. R., Asemota, S., Abdallah, Q. A., Mims, T. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109285 · Cited by 104
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Zou, Y., Wang, S., Zhang, H., Gu, Y., Chen, H., Huang, Z., Yang, F., Li, W., Chen, C., Men, L., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.21989 · Cited by 108
A Review of Current and Pipeline Drugs for Treatment of Melanoma
Natarelli, N., Aleman, S. J., Mark, I. M., Tran, J. T., Kwak, S., Botto, E., Aflatooni, S., Diaz, M. J., & Lipner, S. R. (2024) · Pharmaceuticals · doi:10.3390/ph17020214 · Cited by 114
Spreafico, A., Heirali, A. A., Araujo, D. V., Tan, T. J., Oliva, M., Schneeberger, P. H. H., Chen, B., Wong, M. K., Stayner, L.-A., Hansen, A. R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.011 · Cited by 96
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 135
Microbiota-driven mechanisms at different stages of cancer development
Ivleva, E., & Grivennikov, S. I. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100829 · Cited by 103
The Metabolic Role and Therapeutic Potential of the Microbiome
Olofsson, L. E., & Bäckhed, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac004 · Cited by 107
Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Čížková, J., Cizkova, V., Palanová, A., Horák, V., & Mrázek, J. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02458-5 · Cited by 107
Raufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 110
Clinical translation of microbiome research
Gilbert, J. A., Azad, M. B., Bäckhed, F., Blaser, M. J., Byndloss, M. X., Chiu, C. Y., Chu, H., Dugas, L. R., Elinav, E., Gibbons, S. M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03615-9 · Cited by 123
Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04186-5 · Cited by 123
Gut Microbiome in Colorectal Cancer: Clinical Diagnosis and Treatment
Liu, Y., Lau, H. C.-H., Cheng, W. Y., & Yu, J. Q. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.07.002 · Cited by 119
Rajapakse, J., Khatiwada, S., Akon, A. C., Yu, K. L., Shen, S., & Zekry, A. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2240031 · Cited by 101
Inamura, K., Hamada, T., Bullman, S., Ugai, T., Yachida, S., & Ogino, S. (2022) · Gut · doi:10.1136/gutjnl-2022-327209 · Cited by 100
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Effects of microbiota on anticancer drugs: Current knowledge and potential applications
Huang, J., Liu, W., Kang, W., He, Y., Yang, R., Mou, X., & Zhao, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104197 · Cited by 103
The human microbiome and cancer: a diagnostic and therapeutic perspective
Kandalai, S., Li, H., Zhang, N., Peng, H., & Zheng, Q. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2240084 · Cited by 101
Proteomics, Personalized Medicine and Cancer
Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., & Nice, E. C. (2021) · Cancers · doi:10.3390/cancers13112512 · Cited by 103
Glitza, I. C., Seo, Y. D., Spencer, C. N., Wortman, J. R., Burton, E. M., Alayli, F. A., Loo, C. P., Gautam, S., Damania, A., Densmore, J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0066 · Cited by 87
Self-citationElkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 107
Bladder cancer, inflammageing and microbiomes
Martin, A., Woolbright, B. L., Umar, S., Ingersoll, M. A., & Taylor, J. A. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00611-3 · Cited by 95
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 89
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
Thomas, M. F., Slowikowski, K., Manakongtreecheep, K., Sen, P., Samanta, N., Tantivit, J., Nasrallah, M., Zubiri, L., Smith, N. P., Tirard, A. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02895-x · Cited by 104
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases
Hou, S., Yu, J., Li, Y., Zhao, D., & Zhang, Z. (2025) · Advanced Science · doi:10.1002/advs.202413197 · Cited by 116
The Role of Microbiota in Gastrointestinal Cancer and Cancer Treatment: Chance or Curse?
Smet, A., Kupčinskas, J., Link, A., Hold, G. L., & Bornschein, J. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.013 · Cited by 94
Ballerini, M., Galié, S., Tyagi, P., Catozzi, C., Raji, H., Nabinejad, A., Macandog, A. D. G., Cordiale, A., Slivinschi, B. I., Kugiejko, K. K., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01318-z · Cited by 103
Self-citationLuo, J., Martucci, V. L., Quandt, Z., Groha, S., Murray, M. H., Lovly, C. M., Rizvi, H. A., Egger, J. V., Plodkowski, A. J., Abu-Akeel, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0921 · Cited by 88
Mechanism and strategies of immunotherapy resistance in colorectal cancer
Shan, J., Han, D. H., Shen, C., Lei, Q., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016646 · Cited by 97
Intratumor microbiome in cancer progression: current developments, challenges and future trends
Liu, J., & Zhang, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00381-5 · Cited by 86
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 88
Li, X., Shang, S., Wu, M., Song, Q., & Chen, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217096 · Cited by 92
Relationship of the lung microbiome with PD-L1 expression and immunotherapy response in lung cancer
Jang, H. J., Choi, J. Y., Kim, K., Yong, S. H., Kim, Y. W., Kim, S. Y., Kim, E. Y., Jung, J. Y., Kang, Y. A., Park, M. S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01919-1 · Cited by 90
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Huang, J., Xing, Z., Kang, W., Hao, H., Mao, Y., Zhang, H., Chen, Y., Tan, Y. Q., He, Y., Zhao, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874922 · Cited by 86
Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism
Liu, J., Sun, J., Yu, J., Chen, H., Zhang, D., Zhang, T., Ma, Y., Zou, C., Zhang, Z., Ma, L., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00399-z · Cited by 94
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 85
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 86
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 90
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 97
The gut microbiome and cancer response to immune checkpoint inhibitors
Gazzaniga, F. S., & Kasper, D. L. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184321 · Cited by 92
Zhu, X., Hu, M., Huang, X., Li, L., Lin, X., Shao, X., Li, J., Du, X., Zhang, X., Sun, R., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.12.013 · Cited by 94
Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions
Borella, F., Carosso, A. R., Cosma, S. D., Preti, M., Collemi, G., Cassoni, P., Bertero, L., & Benedetto, C. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00839 · Cited by 82
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer
Boesch, M., Baty, F., Albrich, W. C., Flatz, L., Rodriguez, R., Rothschild, S. I., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1988403 · Cited by 79
Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors
Bredon, M., Danne, C., Pham, H. P., Ruffié, P., Bessede, A., Rolhion, N., Creusot, L., Brot, L., Alonso, I., Langella, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2374954 · Cited by 74
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 81
Group 3 innate lymphoid cells in intestinal health and disease
Horn, V., & Sonnenberg, G. F. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00906-3 · Cited by 87
Véziant, J., Villéger, R., Barnich, N., & Bonnet, M. (2021) · Cancers · doi:10.3390/cancers13092215 · Cited by 80
Zhang, L. R., Wang, Y., Wu, F., Wang, X., Feng, Y., & Wang, Y. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.036 · Cited by 76
Microbiome as an immune regulator in health, disease, and therapeutics
Juarez, V. M., Montalbine, A. N., & Singh, A. K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114400 · Cited by 79
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.